[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651479":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":60,"collaborators":20,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":20,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":20,"enrollmentInfo":72,"targetDuration":20,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":84,"overallStatus":44,"whyStopped":20,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Indiana University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PET\u002FCT 18F-Flurpiridaz Rest\u002FStress Test","EXPERIMENTAL","A two-phase, rest and regadenoson stress evaluated by 18F-Flurpiridaz PET\u002FCT before and 3 months after SOC radiation treatment.",[13,14,15],"Diagnostic Test: PET\u002FCT 18F-Flurpiridaz Rest\u002FStress Test","Device: Coronary CT Angiography (CCTA)","Drug: 18F-Flurpiridaz",[17,21,26],{"type":18,"name":9,"description":11,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST",[9],null,{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":20},"DEVICE","Coronary CT Angiography (CCTA)","Coronary computed tomographic angiography (CCTA) scan is a highly accurate noninvasive technique for detection of coronary artery plaque.",[9],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":20},"DRUG","18F-Flurpiridaz","A two-phase, rest and regadenoson stress evaluated by 18F-Flurpiridaz PET\u002FCT before and 3 months after SOC radiation treatment",[9],[32],{"name":33,"affiliation":5,"role":34},"Jordan Holmes, MD","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":20,"email":40},"Jessica Anders","CONTACT","1 317-278-2722","jemlynn@iu.edu",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Indiana University Melvin and Bren Simon Comprehensive Cancer Center","RECRUITING","Indianapolis","Indiana","46202","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-86.15804,39.76838,{"lat":54,"lon":53},[57,59],{"name":37,"role":38,"phone":58,"phoneExt":20,"email":40},"317-278-2722",{"name":33,"role":34,"phone":20,"phoneExt":20,"email":20},{"type":34,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Jordan A Holmes,","Assistant Professor of Radiology Oncology","100651479","phase-2-prospective-study-on-radiation-induced-cardiotoxicity-assessed-by-pet-ct-for-locally-advanced-non-small-cell-lung-cancer-nsclc-100651479",false,"NCT07761910","Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)","Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Age ≥ 18 at time of consent\n2. Ability to provide written informed consent and HIPAA authorization\n3. Stage III NSCLC per AJCC 8th edition guideline, confirmed by pathological diagnosis and PET\u002FCT.\n4. To receive standard definitive concurrent chemoradiation therapy per NCCN guidelines.\n5. Tumor estimated to be within 2cm of heart contour or anticipated MHD\\>10Gy per treating physician.\n\nExclusion Criteria:\n\n1. Patients treated with stereotactic body radiotherapy (SBRT).\n2. Prior thoracic radiotherapy.\n\nExclusion for Coronary computed tomography angiography (CCTA)\n\n1. History of a severe anaphylactic reaction to iodinated contrast.\n2. Renal insufficiency (defined as estimated CrCl less than 30 mL\u002Fmin).\n3. Inability to hold breath for more than 5 seconds.\n4. Patients on radioactive iodine therapy.\n\nExclusion for 18F-Flurpiridaz PET\u002FCT Test\n\n1. Second-degree AV block, third-degree AV block, and sinus node disease (such as sick sinus syndrome or symptomatic bradycardia) without a functioning pacemaker.\n\n   Note: Resting 12-lead EKG will be ordered at the time of enrollment to be performed prior to PET\u002FCT stress test.\n2. Patients with bronchospastic diseases including asthma and chronic obstructive pulmonary disease (COPD) who have an acute exacerbation or active wheezing (a high-pitched, musical, adventitious lung sound produced by airflow through the narrowed airways) on the day of PET CT exam.\n3. Patients who are hypotensive (systolic blood pressure less than 90 mm Hg) on the day of the PET\u002FCT scan.","ALL","18 Years",{"count":73,"type":74},10,"ESTIMATED","INTERVENTIONAL",[77],"PHASE2","Prospective clinical study designed to evaluate damage to the heart after receiving standard of care chemotherapy and radiation therapy for locally advanced Non-Small Cell Lung Cancer (NSCLC).",[80,81,82,83],"Non Small Cell Lung Cancer","Cardiotoxicity","Locally Advanced Non-Small Cell Lung Cancer","Radiation Therapy",[85,86,87,81],"PET-CT","Radiation Injury","locally advanced Non-Small Cell Lung Cancer","2026-08-10",{"date":90,"type":91},"2026-08-12","ACTUAL",{"date":93,"type":74},"2026-09",{"date":95,"type":74},"2027-03",{"name":5,"class":6},1]